Study of SC-101 for advanced cancers with NECTIN4 gene change
Part of Cancer, Skin clinical trials.
This trial tests a new drug, SC-101, for people with advanced cancers that have a specific change in the NECTIN4 gene. It aims to see if the drug can help shrink or slow the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You are well enough to do daily activities (ECOG score 0 or 1).
- Doctors expect you to live more than 3 months.
- Your cancer has tested positive for a NECTIN4 gene change.
- You do not have unstable tumors in your brain or spinal cord.
- Side effects from past cancer treatments have mostly gone away.
- You have no serious heart or blood vessel problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug (NKT5097) for people with advanced solid tumors that have not responded to other treatments. It may also be an option for people with a specific type of breast cancer (HR+/HER2-). The goal is to see if the drug is safe and effective.
This trial is testing whether a blood test can track how well chemotherapy is working in people with early-stage triple-negative breast cancer. You would provide blood samples before and during treatment, and the results may help your doctor understand your response better.
This trial tests a new drug called SC-101 in people with advanced solid tumors that have not responded to other treatments. It may be an option if your tumor shows a specific protein called Nectin-4, which the drug targets.
This trial tests a new drug called SC-102 in people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if SC-102 is safe and how well it works.
This trial tests a new drug, CRB-701, for people with advanced solid tumors that have a protein called nectin-4 on their surface. It might be an option if other treatments have stopped working or are not available.
This trial tests a new drug, ESG401, for people with triple-negative breast cancer that has come back or spread and cannot be removed by surgery. It compares ESG401 to standard chemotherapy options to see which works better.
Hear when a new HR+ Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.